Bruker Corporation revised revenue guidance for the year 2022. The updated outlook for fiscal year 2022 includes organic revenue growth of 7% to 9% year-over-year, an increase of 1% from prior guidance. This is expected to lead to reported revenue growth in a range of 5% to 7%, consistent with prior guidance.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
80.92 USD | -1.55% | +3.49% | +10.64% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.64% | 11.95B | |
+8.02% | 220B | |
+6.85% | 185B | |
+11.11% | 133B | |
+26.83% | 107B | |
-0.57% | 62.91B | |
+15.90% | 53.34B | |
-1.89% | 47.71B | |
-1.40% | 40.29B | |
+11.15% | 39.57B |
- Stock Market
- Equities
- BRKR Stock
- News Bruker Corporation
- Bruker Corporation Revises Revenue Guidance for the Year 2022